Pendapatan operasional sadurunge ngurangi amortisasi: Seelos Therapeutics Inc. (SEEL)

Seelos Therapeutics develops innovative treatments for psychiatric disorders utilizing various mechanisms of action on the CNS. Analyzing the monthly EBITDA dynamics on GURU.Markets, we find that the value of reflects this status. A critical shortage of funds following failures with a key drug puts the company on the brink of survival. Under these conditions, management is attempting to revise the development portfolio to preserve the residual value of assets.

This indicator measures real cash flow from operating activities, excluding the impact of non-cash charges and tax liabilities to provide an objective assessment of operational efficiency. By analyzing the projected EBITDA level, an investor can compare the fundamental value of Seelos Therapeutics (SEEL) with its speculative potential, assessing the extent to which current CNS research expenditures are justified by the business's actual ability to generate profit.